Signal Detection in Monoclonal and New Agents in Lymphoma
NCT ID: NCT02849912
Last Updated: 2016-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1671 participants
OBSERVATIONAL
2015-04-30
2015-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
After treatment, patients with NHL experienced elevated risks for therapy-related leukemia, several solid tumors and late toxicities such as cardiovascular or neuro-psychiatric diseases which impact on quality of life. However little is known concerning long-term toxicity of this class of new agents so called "targeted drugs" such as anti-CD20.
The primary objective of this cohort study is to estimate long term toxicity in NHL patients (i.e. 10 to 20 years) using data already collected (i.e. internal analysis) and to compare drugs consumption to that of controls (i.e. external analysis).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The LYSA (Lymphoma Study Association) is a national cooperative group which is world pioneer in NHL treatment with novel agents. Patient's bio clinical and demographic characteristics (n=10.000) are fully monitored and stocked in a data base registered in 2006 by the French National Cancer Institute (INCA). The cooperative network of 100 LYSA centre allows following all the patients on long term (up to 20 years after diagnosis).
Then, the mixture of these two sources of data will offer a unique material at the nation scale to detect signal of late onset disease, possibly linked to the initial cancer treatment.
Statistical Methods Disproportionate reporting of drugs consumption in fields of neuro-psychiatric troubles, cardio-vascular diseases, anti-cancer agents, antibiotics and antiviral agents will be extract from the French public healthcare database (external analysis). An economical study is embedded.
As the LYSA data contained all fully monitored patients' bio clinical and demographic characteristics, special attention will be paid to the addition of new agents, in particular anti-CD20 antibody, to the cytotoxic chemotherapy regimens in conjunction with other well-known risk factors (e.g. tobacco, obesity, comorbidities; internal analysis).
Data will be reported according to the initial NHL treatment strategy and cross-validated by long-term medical consultations. Multivariate analysis will be computed to account for competing risks.
Results No studies have yet been published in France on the use of care issues in long remission or cure of cancer. There are very few international publications on this subject and they lacked of statistical power or follow up.
The present project follows the recommendation from the French Medicine Academy which in its March 15, 2011 decision call for more rigorous follow up of new agents in Oncology. In addition, this project is in concordance with the so named "plan cancer 2" from the INCA which aimed to focus on sequels in cancer survivors. If the results of this study are relevant, the investigators should have to run through the consumption of care, a good objective (unbiased) indicator of healing and Health-related quality of life (HRQL) in cancer survivors.
Such an indicator could help to learn about survivors recovery after their cancer, with or without differences according to the patient characteristics, initial location of the cancer, its treatment and possible iatrogenic complications.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
questionnaire
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Follicular lymphoma
* Mantle cell lymphoma
* Previously untreated with chemo- or radiotherapy
* Include in LYSA trial
* Age 18-90 years
Exclusion Criteria
* Previous treatment with chemotherapy or radiation therapy
* Contraindication to any drug contained in the chemotherapy regimen
* Previously known HIV positive serology
* Active hepatitis B or C
* Prior history of malignancies other than lymphoma within 3 years
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Nice
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-PP-09
Identifier Type: -
Identifier Source: org_study_id